These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22761301)

  • 1. Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.
    Lima FA; Ferreira DM; Moreno AT; Ferreira PC; Palma GM; Ferreira JM; Raw I; Miyaji EN; Ho PL; Oliveira ML
    Clin Vaccine Immunol; 2012 Sep; 19(9):1382-92. PubMed ID: 22761301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.
    Ferreira DM; Darrieux M; Silva DA; Leite LC; Ferreira JM; Ho PL; Miyaji EN; Oliveira ML
    Clin Vaccine Immunol; 2009 May; 16(5):636-45. PubMed ID: 19279169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.
    Oliveira ML; Miyaji EN; Ferreira DM; Moreno AT; Ferreira PC; Lima FA; Santos FL; Sakauchi MA; Takata CS; Higashi HG; Raw I; Kubrusly FS; Ho PL
    PLoS One; 2010 May; 5(5):e10863. PubMed ID: 20523738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
    Salcedo-Rivillas C; Debrie AS; Miyaji EN; Ferreira JM; Raw I; Locht C; Ho PL; Mielcarek N; Oliveira ML
    Clin Vaccine Immunol; 2014 Jul; 21(7):972-81. PubMed ID: 24807055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
    Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K
    Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.
    Xu Q; Surendran N; Verhoeven D; Klapa J; Ochs M; Pichichero ME
    Vaccine; 2015 Feb; 33(8):993-1000. PubMed ID: 25597944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
    Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
    Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
    Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
    Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein.
    Huang J; Luo S; Huang M; Zhang T; Min Z; Liu C; Zhang Q; Yang J; Min X
    Microb Pathog; 2019 Apr; 129():206-212. PubMed ID: 30772476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
    Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
    Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal conjugate vaccine modulates macrophage-mediated innate immunity in pneumonia caused by Streptococcus pneumoniae following influenza.
    Mimura K; Kimura S; Kajiwara C; Nakakubo S; Schaller MA; Ishii Y; Standiford TJ; Kunkel SL; Tateda K
    Microbes Infect; 2020 Sep; 22(8):312-321. PubMed ID: 31958572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal immunization with recombinant chimeric pneumococcal protein and cell wall from immunobiotic bacteria improve resistance of infant mice to Streptococcus pneumoniae infection.
    Laiño J; Villena J; Suvorov A; Zelaya H; Ortiz Moyano R; Salva S; Alvarez S
    PLoS One; 2018; 13(11):e0206661. PubMed ID: 30395582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.